miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy

Vera Usuelli1 | Moufida Ben Nasr1,2 | Francesca D’Addio1 | Kaifeng Liu3 | Andrea Vergani2 | Basset El Essawy4,5 | Jun Yang6 | Emma Assi1 | Mayuko Uehara5 | Chiara Rossi7 | Anna Solini8 | Annalisa Capobianco9 | Elena Rigamonti9 | Luciano Potena10 | Massimo Venturini11 | Mario Sabatino12 | Lorena Bottarelli13 | Enrico Ammirati14 | Maria Frigerio14 | Eduardo Castillo-Leon2 | Anna Maestroni1 | Cinzia Azzoni13 | Cristian Loretti1 | Andy Joe Seelam1 | Albert K. Tai15 | Ida Pastore16 | Gabriella Becchi13 | Domenico Corradi13 | Gary A. Visner3 | Gian V. Zuccotti1,17 | Nelson B. Chau18 | Reza Abdi5 | Marcus G. Pezzolesi19 | Paolo Fiorina1,2,16

1International Center for T1D, Pediatric Clinical Research Center “Romeo ed Enrica Invernizzi”, Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy
2Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
3Division of Pulmonary and Respiratory Diseases, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
4Department of Medicine, Al-Azhar University, Cairo, Egypt
5Renal Division, Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
6Institute of Organ Transplantation, Tongji Hospital and Medical College, Huazhong University of Science and Technology, Wuhan, China
7Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
8Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy
9Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy
10Heart Failure and Heart Transplant Program, S. Orsola-Malpighi Hospital, Alma-Mater University of Bologna, Bologna, Italy
11Department of Radiology, San Raffaele Scientific Institute, Milan, Italy
12Department of Cardiothoracic, Transplantation and Vascular Surgery, S. Orsola-Malpighi Hospital, Alma Mater-University of Bologna, Bologna, Italy
13Department of Medicine and Surgery, University of Parma, Parma, Italy
14De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
15Tufts University Core Facility (TUCF) Genomics Core, Tufts University School of Medicine, Boston, Massachusetts
16Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy
17Department of Pediatrics, Buzzi Children’s Hospital, Milan, Italy
18Regulus Therapeutics Inc, San Diego, California
19Division of Nephrology and Hypertension, Diabetes and Metabolism Center, University of Utah, Salt Lake City, Utah

Abbreviations: Arg1, Arginase 1; ATG, thymoglobulin; bm12, C57BL/6 J, B6.C- H2bm12; BMDM, bone marrow-derived macrophages; CAV, chronic allograft vasculopathy; CPM, counts per million; CsA, cyclosporine; CVA, cerebrovascular accident; ddPCR, digital droplet PCR; ECAR, extracellular acidification rate; ELISA, enzyme-linked immunosorbent assay; FACS, flow cytometric analysis; FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; LysMcre, B6.129P2- Lyz2tm1(cre)Ifo/J; miRNAs, MicroRNAs; MMF, mycophenolate; nc miRNA, negative control miRNA antagomir; OCR, oxygen consumption rate; PBS, phosphate-buffered saline; qRT-PCR, real-time quantitative reverse transcription polymerase chain reaction; SEM, standard error mean.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.
Despite much progress in improving graft outcome during cardiac transplantation, chronic allograft vasculopathy (CAV) remains an impediment to long-term graft survival. MicroRNAs (miRNAs) emerged as regulators of the immune response. Here, we aimed to examine the miRNA network involved in CAV. miRNA profiling of heart samples obtained from a murine model of CAV and from cardiac-transplanted patients with CAV demonstrated that miR-21 was most significantly expressed and was primarily localized to macrophages. Interestingly, macrophage depletion with clodronate did not significantly prolong allograft survival in mice, while conditional deletion of miR-21 in macrophages or the use of a specific miR-21 antagonor resulted in indefinite cardiac allograft survival and abrogated CAV. The immunophenotype, secretome, ability to phagocytose, migration, and antigen presentation of macrophages were unaffected by miR-21 targeting, while macrophage metabolism was reprogrammed, with a shift toward oxidative phosphorylation in naïve macrophages and with an inhibition of glycolysis in pro-inflammatory macrophages. The aforementioned effects resulted in an increase in M2-like macrophages, which could be reverted by the addition of L-arginine. RNA-seq analysis confirmed alterations in arginase-associated pathways associated with miR-21 antagonism. In conclusion, miR-21 is overexpressed in murine and human CAV, and its targeting delays CAV onset by reprogramming macrophages metabolism.

**KEYWORDS**

basic (laboratory) research / science, heart (allograft) function / dysfunction, heart transplantation / cardiology, immunobiology, macrophage / monocyte biology: activation, molecular biology: micro RNA, rejection: vascular, translational research / science

---

1 | INTRODUCTION

Cardiac transplantation is the most effective therapy for prolonging survival in patients with end-stage heart failure, and it also provides better survival and quality of life as compared with conventional medical or pharmacological treatment. However, despite much improvement in patient selection, heart preservation, immunosuppression, and cytomegalovirus prophylaxis, the late outcomes of allograft survival have only slightly improved. Chronic allograft vasculopathy (CAV) occurs in 50% of cardiac transplant recipients by 5 years after transplantation and is characterized by neointimal hyperplasia, vascular inflammation, and occlusion; is a major feature of chronic rejection; and continues to limit long-term survival following cardiac transplantation. This type of rejection occurs in the presence of T cell-related immunosuppression confirming the role of other immune cells like macrophages. Indeed, the degree of macrophages infiltration correlates with CAV severity. While the etiology of CAV varies from immune to nonimmune events, no specific treatments are available. MicroRNAs (miRNAs) are short noncoding single-stranded RNAs, many of which have been highly conserved throughout evolution. miRNAs regulate gene expression post-transcriptionally by targeting mRNA for degradation or translational repression and have been implicated in regulation of the immune system and of transplant outcomes. Particularly, miR-21 has been identified as modulator of the alloimmune response in kidney transplant and fibrosis. Interestingly, the miRNA pathway involved in CAV has not yet been discovered. In this study, we used an unbiased approach, in which we profiled the miRNome of samples obtained from a murine model heterotopic vascularized cardiac transplantation in which a minor HLA mismatching between donor/recipient immune repertoire evokes a CAV by 8 weeks after transplantation thus resembling the human CAV. We have also performed miRNA profiling in samples obtained from patients with CAV to delineate the exact miRNA profiles of human CAV. Furthermore, we evaluated the effect of targeting the miRNAs identified with specific miRNA antagonors in order to determine the effect on CAV.

2 | MATERIALS AND METHODS

A detailed description of the methods used in this study is provided in the Data S1.

2.1 | Patients

Heart biopsies were obtained from the right side of the interventricular septum of cardiac transplant recipients. Samples were formalin-fixed, paraffin-embedded, sectioned, and histologically graded by a cardiac pathologist, as per the criteria of the 2005 International Society for Heart and Lung Transplantation.
patients and a description of the immunosuppressive regimens are listed in Table 1 and in Table S1.

Human studies were approved by the appropriate institutional review board.

### 2.2 | Mice

C57BL/6 J, B6.C-H2^dm12 (bm12), and B6.129P2-Lyz2^tm1(cre)Ifj/J (LysM<sup>cre</sup>, stock number 004781) mice were obtained from the Jackson Laboratory. miR-21<sup>fl/fl</sup> mice were kindly provided by Eric Olson (UT Southwestern). miR-21<sup>fl/fl</sup>LysM<sup>Cre</sup> C57BL/6 mice were generated as follows: miR-21<sup>fl/fl</sup> mice were bred with LysM<sup>Cre</sup> mice in order to obtain miR-21<sup>fl/fl</sup>LysM<sup>Cre</sup> C57BL/6 mice, in which miR-21 is flanked by loxP sites and is selectively removed by Cre recombinase expression in LysM-expressing cells, allowing for specific deletion of miR-21 in macrophages. All mice were used and cared for in accordance with institutional guidelines, and animal protocols were approved by the Boston Children’s Hospital Institutional Animal Care and Use Committee.

### 2.3 | Cardiac transplantation

Vascularized cardiac allografts were transplanted intra-abdominally using microsurgical techniques as described by Corry et al. Rejection was determined as complete cessation of cardiac contractility and was confirmed by direct visualization.

### TABLE 1 Patient characteristics (n = 10)

| Year of transplantation | 2005–2014 |
|-------------------------|-----------|
| Sex (M/F)               | 7/3       |
| Age, years              | 39.7 ± 13.75 |
| End-stage heart failure etiology, n (%) | Ischemic cardiomyopathy 3 (30%) Dilated cardiomyopathy 4 (40%) Post-myocarditic cardiomyopathy 1 (10%) Retransplant 1 (10%) Postpartum cardiomyopathy 1 (10%) |
| Immunosuppressive regimen<sup>a</sup> | Induction ATG Maintenance Csa + MMF + prednisone Csa + azathioprine + prednisone Tacrolimus + MMF + prednisone |
| Acute graft rejection episodes<sup>b</sup>, n (%) | 8 (80%) |
| Mortality, n (%) | Squamous cell carcinoma, 1 (10%) |

| Donor | Sex (M/F) | Age, year | Ischemia, min |
|-------|-----------|-----------|---------------|
|       |           | 41.4 ± 15.67 | 164.2 ± 72.51 |

Abbreviations: ATG, thymoglobulin; Csa, cyclosporine; CVA, cerebrovascular accident; MMF, mycophenolate.

Data are expressed as mean ± SD.

<sup>a</sup>Immunosuppressive regimen was subsequently tuned according to patient conditions.

<sup>b</sup>Requiring intravenous steroid treatment.

### 2.4 | miR-21 targeting in vivo

Adult (8–12 weeks) C57BL/6 J mice were transplanted with sex-matched bm12 hearts and received miR-21-specific antagomir or nonspecific negative control oligonucleotide (Regulus and Exiqon) (80 mg/kg) in phosphate-buffered saline (PBS) by intravenous injection. The miR-21 antagomir is a high-affinity oligonucleotide complementary to the active site of miR-21, with a modified backbone.<sup>15,22</sup>

Mice were injected twice per week at Weeks 1 and 2 and once per week at Weeks 3 and 4 after cardiac surgery.

### 2.5 | miR-21 targeting in vitro

Bone marrow–derived macrophages (BMDMs) were treated in vitro with 100 nM of miR-21 antagomir (Exiqon) for 24 h according to the manufacturer’s instructions. Cells and supernatant were collected for analysis.

### 2.6 | Statistics

Data are expressed as mean ± standard error mean (SEM) from at least three independent experiments. Kaplan–Meier curves were used for analysis of survival followed by Log-rank (Mantel–Cox) test. Statistical analysis, other than for RNA-seq results, was performed using Student’s t test with Welch’s correction (if applicable). For Year of transplantation 2005–2014

| Sex (M/F) | 7/3 |
| Age, years | 39.7 ± 13.75 |
| End-stage heart failure etiology, n (%) | Ischemic cardiomyopathy 3 (30%) Dilated cardiomyopathy 4 (40%) Post-myocarditic cardiomyopathy 1 (10%) Retransplant 1 (10%) Postpartum cardiomyopathy 1 (10%) |
| Induction ATG Maintenance Csa + MMF + prednisone Csa + azathioprine + prednisone Tacrolimus + MMF + prednisone |
| Acute graft rejection episodes<sup>b</sup>, n (%) | 8 (80%) |
| Squamous cell carcinoma, 1 (10%) |
| Sex (M/F) | 6/4 |
| Age, year | 41.4 ± 15.67 |
| Ischemia, min | 164.2 ± 72.51 |
The common top 17 miRNAs upregulated at 4 weeks and 8 weeks in allogeneic transplant ranked by mean vs. fold change:

- miR-21-5p
- miR-16
- miR-142-3p
- miR-15a
- miR-15b
- miR-146a
- miR-223
- miR-106a+miR-17
- miR-19b
- miR-19a
- miR-191
- miR-342-3p
- miR-340-5p
- miR-106b
- miR-2135
- miR-155
- miR-93
Multiple comparisons, one-way ANOVA followed by Tukey multiple comparisons analysis between the group of interest and all other groups was used. Volcano plot and differential expression analysis of miRNAs were generated using the edgeR Bioconductor package in R. Differences between the experimental groups were considered statistically significant (*) or highly significant (***) (***), when the p value was <.05, <.01, or <.001, respectively. Graphs were generated using GraphPad Prism software version 6.0 (GraphPad).

2.7 | Study approval

Human and animal studies were approved by the appropriate institutional review board(s) of Niguarda Hospital (Milan, Italy) (80–032013) and Boston Children’s Hospital, Harvard Medical School (Boston, MA) (16–04-3127R). Written informed consent was received from participants prior to inclusion in the study.

3 | RESULTS

3.1 | miR-21 is upregulated in murine heart allografts during CAV

To determine miRNAs potentially involved in CAV, we first profiled the miRNome in the well-characterized minor MHC Class II mismatch murine model of cardiac transplantation (Figure 1A,B). In this model, bm12 hearts are transplanted into C57BL/6 recipients (bm12 into C57BL/6), and cardiac allografts typically survive for approximately 50–70 days without immunosuppression.28,29 Bm12, cardiac allografts are not acutely rejected by C57BL/6 mice but show instead minimal cellular infiltration starting from 1 week after the transplant procedure.30 By Day 40 after the transplant, allografts develop features of chronic rejection with vasculopathy, interstitial inflammation, and myocardial fibrosis, with a scattered distribution of CD4 or CD8 T cells infiltrating the graft and with perivascular clustering of macrophages resembling the features of human CAV.3,21–23 To identify dysregulated miRNAs expressed in murine transplanted hearts and involved in CAV, we chose an early time-point when preclinical signs began to appear (4 weeks) and a later time-point (8 weeks) when the phenotype becomes more severe and was concomitant with the high infiltration of macrophages rather than of T cells or of B cells (Figure S1A–J). Following miRNA microarray analysis, we identified 192 miRNAs that were upregulated or downregulated in murine transplanted heart allografts with CAV compared with syngeneic transplants (bm12 into bm12), which were used as controls (Figure 1A,B). Those with a p value <.05 and mean >6 were considered upregulated and those with a p value <.05 and a mean <6 were considered downregulated. Among these miRNAs, miR-21 was both the most highly expressed and the most robustly upregulated in allogeneic transplanted hearts as compared with syngeneic transplants, displaying a 20-fold increase at 8 weeks (Figure 1B). A common set of 17 miRNAs was found to be upregulated at both 4 and 8 weeks post-transplant (Figure 1C,D). miR-21 upregulation was confirmed by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and digital droplet PCR (ddPCR) (Figure 1E,F), thus validating our array profiling data. In situ hybridization demonstrated that the miR-21 hybridization signal was greatly enhanced in allogeneic transplanted hearts as compared with syngeneic transplanted hearts (Figure 1G,H). miR-21 was the most highly upregulated miRNA in murine transplanted heart allografts with CAV as compared with controls.

3.2 | miR-21 is upregulated in human heart allografts during CAV

We next obtained human transplanted heart samples from cardiac-transplanted patients, with and without features of CAV (Table 1 and Table S1). miRNome profiling of human heart biopsies revealed 666 miRNAs of interest after filtering out nondetectable miRNAs (miRNAs having an expression level of >1 counts per million [CPM] in at least two samples were considered detectable). miR-21 again showed the highest expression and most robust upregulation in heart samples obtained from cardiac-transplanted patients with CAV compared with samples obtained from patients without CAV (Figure 2A). In addition to miR-21, we found 16 other miRNAs potentially important for cardiac-transplanted patients that were upregulated in CAV (Figure 2B) but to a lesser degree than miR-21.
miR-21 upregulation in CAV subjects was confirmed by qRT-PCR and ddPCR (Figure 2C,D). In situ hybridization showed some upregulation of miR-21 within heart samples of cardiac-transplanted patients with CAV as compared with samples from patients without CAV (Figure 2E,F,G). The presence of a robust miR-21 upregulation in our samples was particularly associated with the presence of heart allograft-infiltrating macrophages Mac-2+ cells as shown in Figure 2H–I. Altogether, our data demonstrated that miR-21 was the highly upregulated miRNA in heart allograft samples from cardiac-transplanted patients with CAV as compared to those without CAV.

3.3 | miR-21-expressing macrophages play a role in CAV onset

In order to understand which cells were responsible for miR-21 upregulation during CAV, we injected Cy3-labeled anti-miR-21 oligonucleotide into C57BL/6 mice transplanted with bm12 hearts. Mice were injected after 8 weeks post-transplantation on Day 55, and heart allografts were examined after 24 h on Day 56, allowing for examination of miR-21 localization within heart allografts. Interestingly, miR-21 was detected in graft-infiltrating macrophages (Mac-2+), but not in B (B220+) or T cells (CD3+) (Figure 3A–B), while myocytes appeared completely negative for miR-21 (data not shown). We further quantified the percentage of miR-21+ macrophages within the total population of macrophages and miR-21+ macrophages appeared to be approximately the 40% of the total macrophages (Figure 3C). qRT-PCR analysis of splenocytes obtained from naïve C57BL/6 mice confirmed that in F4/80+ cells, the expression of miR-21 was significantly higher in those cells as compared with CD11c+, CD3+ and CD19+ cells (Figure S1K). To further determine whether miR-21 upregulation in macrophages is relevant during CAV onset, we used a murine model of CAV (C57BL/6 mice transplanted with bm12 hearts), in which we first treated heart-transplanted mice with clodronate in order to deplete the circulating macrophage pool. Clodronate, which has been extensively used previously to deplete macrophages, was injected every 5 days beginning at Day 1 following heart transplantation; another group of mice were left untreated and used as controls (Figure 3D). The depletion of macrophages from peripheral blood was confirmed by flow cytometry as revealed by a decrease in CD115+ monocytes cells (Figure 3E,F) and in heart-allograft by a reduced infiltration of macrophages as shown by the scarce immunohistochemical staining of Mac-2 (Figure 3G–H) and by a decrease in F4/80 expression as revealed by qRT-PCR (Figure 3I). A nonsignificant delay in CAV onset was observed in clodronate-treated mice as compared with controls (Figure 3D). Interestingly, macrophage depletion following clodronate treatment was shown to correlate miR-21 expression in heart-allografts as assessed by qRT-PCR (Figure 3I) and by in situ hybridization (Figure 3J). Due to the fact that clodronate removes all macrophages regardless of miR-21 expression, we then decided to conditionally delete miR-21 in macrophages by using the miR-21 fl/flLysMCre C57BL/6 mouse. In this mouse, the miR-21 is flanked by loxP sites and is selectively removed by Cre recombinase expression in LysM-expressing cells (under the control of the LysM promoter, present in macrophages and some myeloid cells), such that miR-21 deletion occurs specifically in macrophages. miR-21 fl/flLysMCre C57BL/6 mice receiving bm12 hearts showed a prolonged and indefinite cardiac allograft survival as compared to control cardiac-transplanted littermate mice (Figure 3D). miR-21 fl/flLysMCre cardiac-transplanted mice displayed a reduction in miR-21 expression in heart allografts as analyzed by qRT-PCR (Figure 3I) and in situ hybridization (Figure 3J) as compared with controls (Figure 3J). In order to understand if the observed beneficial effect on allograft survival was associated with any altered survival of the macrophages, we quantified the percentage of apoptotic macrophages within the graft by using caspase 3 staining and we confirmed the absence of any differences (Figure S2A). Lastly, as an aberrant proliferation of activated vascular smooth muscle cells (VSMCs) has been associated to CAV, we thus sought to investigate if any effect by miR-21 targeting was evident on VSMCs. Importantly, VSMCs within the cardiac allograft from miR-21 LysMCre mice kept their quiescent no-proliferating status, as revealed by a negative PCNA staining in the smooth muscle cells of the tonaca media (Figure S2B,C). Altogether, these data suggest that specific depletion of miR-21+ macrophages rather than complete macrophage depletion might have a beneficial effect over prolongation of heart allograft survival in a murine model of CAV.
3.4 | miR-21 antagonism abrogates CAV

In order to establish a proof of concept for the potential role and effect of miR-21 targeting in CAV, we tested in vivo the efficacy of a miR-21 specific antagonist. The miR-21-specific antagonist is a nontoxic oligonucleotide complementary to miR-21, with a chemically modified backbone as described in Section 2. While untreated C57BL/6 mice transplanted with bm12 hearts rejected heart allografts between 4 and 8 weeks post-transplant (Figure 4A), mice treated with miR-21 antagonist displayed long-term heart allograft survival (>95 days) in 100% of recipients (Figure 4A). To further characterize the effect of in vivo miR-21 targeting, we analyzed the infiltrate of cardiac transplants isolated from miR-21 antagonist-treated and in control mice. Pathological examination of allografts obtained at 8 weeks post-transplantation (Figure 4B–J) revealed that miR-21 antagonist-treated mice showed reduced mononuclear cell infiltration, particularly with respect to Mac-2+ macrophages (Figure 4E_{2,5,G}) in the graft infiltrate as compared to controls (Figure 4E_{2,5,G}). Reduced vasculopathy in the cardiac perivascular space was evident by hematoxylin and eosin staining respectively in grafted heart tissue obtained from miR-21 antagonist-treated mice (Figure 4E_{5,F}) as compared with controls (Figure 4E_{5,F}). Significant reduction in the number of CD3+ cells was observed when comparing miR-21 antagonist-treated (Figure 4E_{5,F,G,H}) to control mice (Figure 4E_{3,5,F,G,H}). Quantitative analysis confirmed a reduction in degree of cell infiltration (Figure 4B), vasculopathy (Figure 4C), and luminal stenosis (Figure 4D) in miR-21 antagonist-treated mice as compared with controls. Moreover, we observed a reduction in the degree of fibrosis as evaluated with Masson’s trichrome staining in miR-21 antagonist-treated mice (Figure 4I_{1,3,J}) compared with controls (Figure 4I_{1,3,J}). We then evaluated the immune profile of miR-21 antagonist-treated mice by flow cytometry and gene expression analysis by qRT-PCR (Figure S3). In miR-21 antagonist-treated mice, immunophenotyping the percentage of macrophages in the allograft and in the spleen of miR-21 antagonist-treated mice and controls was similar (Figure S3A,K). Moreover, no differences were detected in the M1 phenotype markers CD80, CD86 (Figure S3B,C,L,M) or in the M2 phenotype marker CD206 (Figure S3D,N) in the allograft and in the spleen of miR-21-specific antagonist-treated as compared to controls. We found high levels of Arg1 mRNA and of Nos2 mRNA in the spleen, but not in the allograft of miR-21 antagonist treated mice as compared with controls (Figure S3E,F,O,P). Interestingly, in miR-21 antagonist-treated mice, T cells expressed higher levels of GATA-3 in both allograft (Figure S3G) and spleen (Figure S3Q) as compared with controls. Moreover, in miR-21 antagonist-treated mice, T cells obtained from allograft (Figure S3H,I), but not spleen (Figure S3R,S), expressed higher levels of T-beta and RORc, with no differences in the overall percentage of CD4+ T cells (Figure S2J,T). To further assess whether the treatment with miR-21 antagonist have any effect on T cells, we evaluated the percentage of IFN-γ+CD4+ and IFN-γ+CD8+ T cells generated during an anti-CD3/28 stimulation of murine splenocytes in the presence/absence of miR-21 antagonist. Our data showed no significant difference in the percentage of the different T cell subsets during miR-21 targeting (Figure S4A–D). On the contrary, there was a slight significant difference when comparing CD4+ and CD8+ proliferating T cells exposed or not to miR-21 antagonist (Figure S4E,F). miR-21 antagonism promotes allograft survival thereby reducing cell infiltration, vasculopathy and fibrosis.

3.5 | miR-21 antagonism reshapes macrophages profiles in vitro

We next expanded our investigation to further understand the effect of miR-21 antagonist on the macrophage immune profile...
by using a BMDM-based in vitro assay. Uncommitted BMDMs M0 were polarized into M1, using IFN-γ, or to M2, using IL-4, IL-10 and IL-13 (Figure S5A). M1 or M2 differentiation was confirmed by the presence of M1-specific markers (CD80+ and CD86+) or M2-specific markers (CD206+) (Figure S5B). We then challenged BMDMs with the miR-21 antagonir, which reduced miR-21 expression in M0, M1, and M2 macrophages (Figure 5A–C). miR-21 antagonism modified the macrophage immune profile.
as shown by an increase in Arg1 gene expression, while the levels of NOS2 remained unaltered (Figure 5A–C). No differences were observed in expression of CD80, CD86, or CD206 in M0, M1, and M2 macrophages following challenge with the miR-21 antagonist (Figure 5D–F). Next, we analyzed the secretome profile of macrophages following treatment with the miR-21 antagonist, which did not reveal any significant differences in levels of IL-1β and IL-6 (Figure 5G–I). A slight increase in TNF-α secretion was observed in M2 macrophages following miR-21 antagonist (Figure 5I). Levels of TGF-β, MIG, and IL-12 decreased in M0 macrophages (Figure 5G) but not in M1 and M2 macrophages (Figure 5H,I). Finally, the use of miR-21 antagonist was found to exert no significant effects on macrophage phagocytosis, migratory ability, or antigen-presenting properties (Figure 5J–M). We also assessed the effect of miR-21 targeting on M0-, M1-, and M2-derived macrophages; indeed, the percentage of apoptotic macrophages was not affected by miR-21 antagonist, while a slight reduction in the percentage of necrosis was observed in M2-derived macrophages (Figure 5G–K). Taken together, our results indicate that miR-21 antagonism only slightly modulates the immune profile of in vitro generated macrophages without affecting their main functional properties (phagocytosis, migration, and antigen presentation).

### 3.6 miR-21 antagonism reprograms macrophage metabolism

We then performed RNA-seq profiling of BMDMs after in vitro challenge with the miR-21 antagonist. Our data revealed that 230 genes were altered by miR-21 antagonism (Figure 6A and S6A), with 116 upregulated genes and 114 downregulated genes (Figure S6B,C). As shown in Figure 6B, among those genes that were upregulated, many are known to be involved in determining or accompanying the M2 phenotype (Figure 6B and S6B,D), or correlated with anti-inflammatory pathways, while others are involved in fatty acid oxidation and primary metabolic pathways (Figure 6B and S6B). Consistent with these data, within the downregulated genes were found those linked with M1 signature and IFN-γ and other inflammatory pathways (Figure 6C and S6C). Finally, using ingenuity pathway analysis in an attempt to connect those upregulated/downregulated genes following miR-21 antagonism revealed a rewiring of the transcriptional regulatory network of macrophages to adopt an anti-inflammatory phenotype consistent with the acquisition of some anti-inflammatory signatures (Figure S7). We next more extensively characterized the macrophage metabolic profile upon challenge with a miR-21 antagonist by evaluating cellular metabolic function (Figure 6D–Q). Our data demonstrated an increase in oxygen consumption rate (OCR), an indicator of an optimal mitochondrial function, in M0 macrophages following treatment with the miR-21 antagonist (Figure 6D,E) as compared with baseline conditions (Figure 6D,E,I), while in M2 macrophages, OCR was unchanged (Figure 6D,E,J). Given the changes in Arginase expression, we previously observed with miR-21 antagonism, we evaluated the effect of reconstituting L-arginine during challenge with the miR-21 antagonist. L-Arginine added during treatment with the miR-21 antagonist significantly increased OCR in M1 macrophages (Figure 6F,I), decreased OCR in M2 macrophages (Figure 6F,J), and had no effect on M0 macrophages (Figure 6F,H). Interestingly, the use of the miR-21 antagonist robustly reduced the extracellular acidification rate (ECAR), an indicator of glycolysis, in M1 macrophages, while L-Arginine was shown to abrogate this effect (Figure 6K,L,P). In M0 macrophages, the use of the miR-21 antagonist enhanced ECAR, while L-Arginine was poorly effective (Figure 6K–O). Finally, in M2 macrophages a marked increase in ECAR was evident with L-arginine following miR-21 antagomir treatment and it was slightly decreased by the addition of L-arginine (Figure 6K–N,Q). Interestingly, a decrease in glycolysis, maximum glycolytic capacity and glycolytic reserve were evident in M1 macrophages in the presence of the miR-21 antagonist, while L-arginine abrogated its effect (Figure S8B,E,H). An increase in glycolysis, maximum glycolytic capacity and glycolytic reserve was observed in M0 and M2 macrophages in the presence of the miR-21 antagonist (Figure S8A,C,D,F,G,I), and the addition of L-arginine following miR-21 antagonist treatment contributed to these effects (Figure S8A,C,D,F,G,I). Collectively, these data suggest that miR-21 antagonism modulates the metabolic profile of in [Figure 6H,I]. Finally, the use of miR-21 antagomir was found to exert no significant effects on macrophage phagocytosis, migratory ability, or antigen-presenting properties (Figure 5J–M). We next more extensively characterized the macrophage metabolic profile upon challenge with a miR-21 antagonist by evaluating cellular metabolic function (Figure 6D–Q). Our data demonstrated an increase in oxygen consumption rate (OCR), an indicator of an optimal mitochondrial function, in M0 macrophages following treatment with the miR-21 antagonist (Figure 6D,E) as compared with baseline conditions (Figure 6D,E,I), while in M2 macrophages, OCR was unchanged (Figure 6D,E,J). Given the changes in Arginase expression, we previously observed with miR-21 antagonism, we evaluated the effect of reconstituting L-arginine during challenge with the miR-21 antagonist. L-Arginine added during treatment with the miR-21 antagonist significantly increased OCR in M1 macrophages (Figure 6F,I), decreased OCR in M2 macrophages (Figure 6F,J), and had no effect on M0 macrophages (Figure 6F,H). Interestingly, the use of the miR-21 antagonist robustly reduced the extracellular acidification rate (ECAR), an indicator of glycolysis, in M1 macrophages, while L-Arginine was shown to abrogate this effect (Figure 6K,L,P). In M0 macrophages, the use of the miR-21 antagonist enhanced ECAR, while L-Arginine was poorly effective (Figure 6K–O). Finally, in M2 macrophages a marked increase in ECAR was evident with L-arginine following miR-21 antagomir treatment and it was slightly decreased by the addition of L-arginine (Figure 6K–N,Q). Interestingly, a decrease in glycolysis, maximum glycolytic capacity and glycolytic reserve were evident in M1 macrophages in the presence of the miR-21 antagonist, while L-arginine abrogated its effect (Figure S8B,E,H). An increase in glycolysis, maximum glycolytic capacity and glycolytic reserve was observed in M0 and M2 macrophages in the presence of the miR-21 antagonist (Figure S8A,C,D,F,G,I), and the addition of L-arginine following miR-21 antagonist treatment contributed to these effects (Figure S8A,C,D,F,G,I). Collectively, these data suggest that miR-21 antagonism modulates the metabolic profile of in...
vitro generated macrophages, with altered wide modifications of the catabolic metabolism in pro-inflammatory M1 macrophages in an arginine-dependent manner.

4 | DISCUSSION

Cardiac allograft vasculopathy (CAV) is a hallmark of cardiac chronic rejection and constitutes the primary limitation in long-term survival of allografts. It is therefore critical to develop novel strategies to achieve stable graft acceptance and to reduce the incidence of CAV. In order to discover pathways that may be involved in CAV onset and identify new therapeutic targets, we first performed miRnomic profiling of murine and human transplanted hearts, which demonstrated that miR-21 is the most highly expressed miRNA in transplanted hearts with allograft vasculopathy. Most, if not all, of the miR-21 expressed within the transplanted heart was found to be localized into the cytoplasm of cardiac-infiltrating inflammatory cells, which are predominantly macrophages. Several studies have identified miR-21 as a key controller of immune regulation, and so we sought to delineate the role of miR-21-expressing macrophages in the onset of CAV. We first depleted circulating macrophages with clodronate and then conditionally deleted miR-21 in macrophages. Only conditional deletion of miR-21 in macrophages, but not complete macrophage depletion, was successful in prolonging cardiac allograft survival. Indefinite graft survival was also observed using a miR-21-specific antagonist. While clodronate-mediated macrophage depletion is nonspecific and macrophages are depleted independently of their activation state and function, specific genetic deletion of miR-21 as well as the use of a miR-21-specific antagonist specifically targets miR-21-expressing macrophages, thus eventually involved in chronic alloimmune processes. This might be explained by the fact that total macrophage deletion may also target and eliminate regulatory macrophages, while miR-21 genetic or pharmacologic targeting on macrophages, may have instead targeted pro-inflammatory macrophages only, thus contributing to the observed beneficial effect on allograft survival. We then showed that the use of a miR-21 antagonist reshapes macrophage phenotype, as demonstrated by phenotypic and RNA-seq profiling as shown by the increased expression of Arginase-1 activity in addition to a number of other genes, which indicate that these macrophages may exhibit increased anti-inflammatory properties. Interestingly our in vitro studies confirm a wide reshaping of macrophages metabolism when miR-21 is antagonized, with an increase of macrophages glycolytic activity following miR-21 antagonism. The M1 macrophage bioenergetic profile was completely altered by the use of a miR-21 antagonist, with downregulation of OXPHOS activity and glycolytic capacity. Interestingly, the addition of l-arginine during challenge with the miR-21 antagonist reinstated the M1 metabolic profile to baseline status, thus confirming that the miR-21 antagonist effect is dependent upon the l-arginine metabolic pathway. M0 macrophages adopted a more M2-like bioenergetic profile following challenge with a miR-21 antagonist, as demonstrated by an upregulation of their related OXPHOS and glycometabolic activities, with no effects upon the addition of l-arginine. Altogether, miR-21 antagonism skews M0 macrophages such that they adopt an M2-like bioenergetic profile, as well as abrogates M1-related metabolic activity, thus favoring the establishment of an anti-inflammatory environment. Indeed, our data demonstrated a shift in the macrophages metabolic profile upon miR-21 targeting, which appeared to be in line with our recent paper in which conditional deletion of miR-21 in macrophages reprogrammed macrophages metabolism and created an anti-tumor immunity. We recognized that the downstream mechanism underlying miR21-macrophages particularly in CAV may not be completely elucidated by our study. We suggest that miR-21 genetic or pharmacologic deletion on macrophages modified the macrophage metabolism. An inhibition of glycolysis in pro-inflammatory M1 macrophages may dampen macrophages inflammatory response. Indeed, immune metabolic reprogramming and particularly reprogramming of aerobic glycolysis plays a crucial role during macrophage-mediated inflammatory response. Aberrant aerobic glycolysis was reported to be a main mediator of systemic inflammation and thus it may trigger an overall inflammatory reaction leading to organ damage and allograft rejection. Furthermore, the role of miR-21 in macrophages during LPS-induced sepsis and in controlling glycolysis in myeloid cells has been recently observed thus confirming a relevant metabolic/inflammatory role for miR-21. Interestingly, in a different setting, miR-21 has been described as an oncomir and its genetic targeting led to the development of smaller tumors as compared with WT. The aforementioned anti-tumor effect was ascribed to a reshaping of tumor-associated macrophages, with a rewiring of their regulatory activity toward a pro-inflammatory angiostatic phenotype. This was described in a different setting, in which tumor microenvironment may play a role. Interestingly, a miR-21 antagonist-based phase II clinical trial is planned in patients with Alport syndrome. In summary, our study indicates that
(A) M2 signature genes

(B) Anti-inflammatory pathways

(C) M1 signature genes

(D) M1 signature genes

(E) miR-21 antagonir

(F) miR-21 antagonir + L-Arginine

(G) L-Arginine

(H) M0

(I) M1

(J) M2

(K) Medium

(L) miR-21 antagonir

(M) miR-21 antagonir + L-Arginine

(N) L-Arginine

(O) M0

(P) M1

(Q) M2

Legend:
- Up-regulated genes
- Down-regulated genes

Graphs show changes in OCR (oxygen consumption rate) and ECAR (extracellular acidification rate) over time in different conditions and treatments.
miR-21 plays a role in the onset of CAV and that miR-21 antagonism has the potential to abrogate the onset of CAV by reprogramming macrophages metabolism.

ACKNOWLEDGMENTS
We thank the Fondazione Romeo and Enrica Invernizzi for the enormous support. We thank Mollie Jurewicz for editing. We are thankful to Eric Olson (UT Southwestern) for providing miR-21-fl/fl mice. We thank Edoardo Bonacina (Niguarda Hospital) for collection and analysis of human cardiac biopsies. We would also like to thank Maya Fedeli (San Raffaele Scientific Institute) for helpful discussions. P. F. and F. D are supported by the Italian Ministry of Health grant RF-2016-02362512. R. A. is supported by K24 AI116925. V. U. is supported by Fondazione Diabete Ricerca (FO.DI.RI) Società Italiana di Diabetologia (SID) fellowship.

DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

AUTHOR CONTRIBUTIONS
V.U. and M.B.N. designed the study, performed experiments, analyzed data, and wrote the paper; F.D., L.K., A.V., M.U., C.R., E.C.L., and F.D. are supported by the Italian Ministry of Health grant RF-2016-02362512. R. A. is supported by K24 AI116925. V. U. is supported by Fondazione Diabete Ricerca (FO.DI.RI) Società Italiana di Diabetologia (SID) fellowship.

DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available in the main text and in the supporting information of this article.

ORCID
Enrico Ammirati https://orcid.org/0000-0002-1676-5257
Paolo Fiorina https://orcid.org/0000-0002-1093-7724

REFERENCES
1. Davis MK, Hunt SA. State of the art: cardiac transplantation. Trends Cardiovasc Med. 2014;24(8):341-349.
2. Johnson MR, Aaronson KD, Canter CE, et al. Heart retransplantation. Am J Transplant. 2007;7(9):2075-2081.
3. Vergani A, Tezza S, D’Addio F, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation. 2013;127(4):463-475.
4. D’Addio F, Ueno T, Clarkson M, et al. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PloS One. 2013;8(4):e60391.
5. D’Addio F, Boenisch O, Magee CN, et al. Prolonged, low-dose antithymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PloS One. 2013;8(1):e53797.
6. Hosenpud JD, Shipleys GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant. 1992;11(1 Pt 1):9-23.
7. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: 29th official adult heart transplant report–2012. J Heart Lung Transplant. 2012;31(10):1052-1064.
8. Sarraj B, Ye J, Aki Al, et al. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc Natl Acad Sci U S A. 2014;111(33):12145-12150.
9. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207(8):1589-1597.
10. Mannon RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? Curr Opin Organ Transplant. 2012;17(1):20-25.
11. Toki D, Zhang W, Hor KLM, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14(9):2126-2136.
12. Seki A, Fishbein MC. Predicting the development of cardiac allograft vasculopathy. Cardiovasc Pathol. 2014;23(5):253-260.
13. Edwards LA, Nowocin AK, Jafari NV, et al. Chronic rejection of cardiac allografts is associated with increased lymphatic flow and cellular trafficking. Circulation. 2018;137(5):488-503.
